Tonix Pharmaceuticals Holding Corp (TNXP)
0.2042
+0.01
(+7.47%)
USD |
NASDAQ |
Nov 21, 16:00
0.1872
-0.02
(-8.33%)
After-Hours: 05:17
Tonix Pharmaceuticals Enterprise Value: 17.92M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 17.92M |
| November 20, 2024 | 15.27M |
| November 19, 2024 | 10.17M |
| November 18, 2024 | 4.616M |
| November 15, 2024 | 4.261M |
| November 14, 2024 | 5.924M |
| November 13, 2024 | 6.148M |
| November 12, 2024 | 6.859M |
| November 11, 2024 | 1.594M |
| November 08, 2024 | 1.703M |
| November 07, 2024 | 1.734M |
| November 06, 2024 | 1.547M |
| November 05, 2024 | 1.843M |
| November 04, 2024 | 1.828M |
| November 01, 2024 | 1.438M |
| October 31, 2024 | 2.372M |
| October 30, 2024 | 3.788M |
| October 29, 2024 | 5.905M |
| October 28, 2024 | 7.617M |
| October 25, 2024 | 5.516M |
| October 24, 2024 | 4.738M |
| October 23, 2024 | 5.905M |
| October 22, 2024 | 7.773M |
| October 21, 2024 | 9.313M |
| October 18, 2024 | 7.773M |
| Date | Value |
|---|---|
| October 17, 2024 | 7.679M |
| October 16, 2024 | 4.504M |
| October 15, 2024 | 1.703M |
| October 14, 2024 | 3.104M |
| October 11, 2024 | 2.730M |
| October 10, 2024 | 1.610M |
| October 09, 2024 | 2.372M |
| October 08, 2024 | 1.641M |
| October 07, 2024 | 2.154M |
| October 04, 2024 | 1.454M |
| October 03, 2024 | -0.6315M |
| October 02, 2024 | 0.0688M |
| October 01, 2024 | 0.847M |
| September 30, 2024 | 2.870M |
| September 27, 2024 | 24.77M |
| September 26, 2024 | 23.45M |
| September 25, 2024 | 22.75M |
| September 24, 2024 | 22.53M |
| September 23, 2024 | 23.22M |
| September 20, 2024 | 24.98M |
| September 19, 2024 | 24.91M |
| September 18, 2024 | 22.89M |
| September 17, 2024 | 23.13M |
| September 16, 2024 | 23.19M |
| September 13, 2024 | 24.38M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-123.23M
Minimum
Dec 19 2022
570.61M
Maximum
Feb 11 2021
18.00M
Average
4.697M
Median
Enterprise Value Benchmarks
| Emergent BioSolutions Inc | 1.022B |
| Geovax Labs Inc | 16.88M |
| Abbott Laboratories | 210.81B |
| Amicus Therapeutics Inc | 2.978B |
| United Therapeutics Corp | 13.47B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.21M |
| Revenue (Quarterly) | 2.822M |
| Total Expenses (Quarterly) | 16.71M |
| EPS Diluted (Quarterly) | -0.23 |
| Gross Profit Margin (Quarterly) | 44.90% |
| Profit Margin (Quarterly) | -503.6% |
| Earnings Yield | -49.46K% |
| Normalized Earnings Yield | -43648.46 |